However, CD47-blocking as a monotherapy shows limited anti-tumor effects in the pancreatic ductal adenocarcinoma (PDAC) model, which may be related to the limited phagocytosis of macrophages after CD47 blockade. This evidence concerns the gene CD47 and pancreatic ductal adenocarcinoma.